
Novo Nordisk Aims for the Top: CagriSema Poised for Breakthrough
The company hopes to differentiate itself as it faces strong competition from Eli Lilly’s Zepbound, which has already demonstrated greater weight loss, and other upcoming therapies that may offer simpler dosing options.
As Novo prepares for critical clinical trial results due in December, the pressure is mounting, particularly after a 25% drop in stock value linked to lower-than-expected prescriptions for Wegovy and investor concerns